Bristol Myers Squibb Co (BMY) stock
Close on Nov 12, 2026Market cap $127.39BP/E 13.8Yield 4.00%
Bristol Myers Squibb Co grew revenue 4.2% to $50.03B over the twelve months to Sep 30, 2026. Free cash flow was $9.29B, down 39.3% from a year earlier. At the latest close the market valued the company at $127.39B, 13.8 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $127.39B
- P/E ratio
- 13.8
- Price to sales
- 2.55
- Price to book
- 5.44
- Dividend yield
- 4.00%
- Free cash flow yield
- 7.29%
Fundamentals
- Revenue
- $50.03B
- Net income
- $9.24B
- EPS, diluted
- $4.51
- Free cash flow
- $9.29B
- Book value per share
- $11.40
- Diluted shares
- 2.05B
Trading
- Next earnings
- Feb 4, 2027 (estimated, before the open)
- Previous close
- $62.91
- Open
- $63.80
- Day's range
- $62.31 – $64.12
- Volume
- 9,390,192
- Average volume (20 days)
- 10,342,024
- Index membership
- S&P 500, Russell 1000, Russell 3000
- Beta (5 years)
- 0.25
- 52-week range
- $45.27 – $68.64
- RSI (14 days)
- 51.5
- Volatility (1 year)
- 27.8%
- Relative volume
- 0.83×
- WACC
- 6.5%
On 2 of our idea lists: Dividend growers, High yield, covered
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | BMY | S&P 500 | Difference | BMY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.2% | -2.7% | +10.9 pts | ||
| 3 months | -1.2% | -1.7% | +0.6 pts | ||
| Year to date | +20.7% | +11.9% | +8.8 pts | ||
| 1 year | +32.6% | +12.0% | +20.6 pts | ||
| 3 years | +41.8% | +78.2% | −36.3 pts | +12.4% | +21.2% |
| 5 years | +29.0% | +73.2% | −44.3 pts | +5.2% | +11.6% |
| 10 years | +57.8% | +309.6% | −251.9 pts | +4.7% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Net income
EPS, diluted
Free cash flow
Press releases
Releases Bristol Myers Squibb filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Bristol Myers Squibb
Pharmaceutical Preparations
Bristol-Myers Squibb Company engages in the discovery, development, licensing, and commercialization of biopharmaceutical products. Its commercial portfolio and drug development pipeline encompass therapies across multiple therapeutic areas, including immunology, oncology, cardiovascular, hematology, and neuroscience. The company organizes its product offerings into growth brands—such as Opdivo, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati, and Cobenfy—alongside legacy brands including Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel, and Abraxane. It generates revenue via direct net product sales, collaborative agreements, and royalties. Key customers and major wholesale distributors include McKesson Corporation, Cencora, and Cardinal Health.
Company profile, executives and historyBristol Myers Squibb stock: common questions
What is Bristol Myers Squibb's stock price?
BMY closed at $62.32 on Nov 12, 2026, down 0.94% on the day. Over the past 52 weeks it traded between $45.27 and $68.64.
What is Bristol Myers Squibb's market cap?
Bristol Myers Squibb was worth $127.39B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is BMY's P/E ratio?
BMY trades at 13.8 times earnings, based on diluted earnings per share of $4.51 over the twelve months to Sep 30, 2026.
How much revenue does Bristol Myers Squibb make?
Bristol Myers Squibb reported revenue of $50.03B for the twelve months to Sep 30, 2026, up 4.2% from a year earlier.
Does Bristol Myers Squibb pay a dividend?
Yes. Bristol Myers Squibb paid $2.49 per share over the last twelve months, a yield of 4.00% at the latest price, and has raised its annual dividend 18 years in a row.
When does Bristol Myers Squibb report earnings next?
Bristol Myers Squibb is expected to report Q4 FY2026 results on Feb 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has BMY stock performed over the past year?
Including dividends, BMY returned +32.6% over the past year, against +12.0% for the S&P 500.
How many BMY shares are sold short?
47M shares were sold short at the latest FINRA report, 2.29% of the float, or 4.2 days of average trading volume.
Who are Bristol Myers Squibb's competitors?
Companies most similar to Bristol Myers Squibb by business, industry and size include ABBV, AZN, PFE, GSK, AMGN.
See a number that looks wrong?